Brain cancer is an overgrowth of cells in the brain that forms masses called tumors. It is a brain disorder in which cancer cells (malignant cells) arise in the brain tissue. Cancer cells multiply to produce a mass of cancer tissue (tumor) that interferes with brain functions such as muscle control, sensation, memory, and other body functions. Cancer cells that arise from brain tissue are called primary brain tumors, while tumors that spread from other parts of the body to the brain are called metastatic or secondary brain tumors.
Primary brain tumors can develop from a variety of brain tissues (for example, glial cells, astrocytes, and other brain cell types). Metastatic brain cancer is caused by the spread of cancer cells from a body organ to the brain. According to an article published in “Cancer Treatment Centers of America”, on September 2021, individuals with exposure to certain industrial chemicals or solvents were linked to an increased risk in developing brain cancer.
The global brain cancer therapeutics market is valued at US$ 2,539.0 million in 2021 and is expected to exhibit a CAGR of 9.8% during the forecast period (2021-2028).
Figure 1.Global Brain Cancer Therapeutics Market Share (%) in Terms of Value, by Indication, 2021
Increasing morbidity of brain cancer is expected to drive the market growth during the forecast period.
An increase in the prevalence of brain cancer is expected to drive the global brain cancer therapeutics market growth over the forecast period. For instance, according to the American Association of Neurological Surgeons (AANS), a scientific and educational association, approximately 200,000 new cases of brain metastases are diagnosed in the U.S. each year, and the number is expected to be growing with increased awareness and improved diagnostic techniques.
|Base Year:||2020||Market Size in 2021:||US$ 2,539.0 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||9.8%||2028 Value Projection:||US$ $ 4,897.4 Mn|
Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, Johnson & Johnson, Merck & Co, Bayer AG, and Bristol-Myers Squibb Company
|Restraints & Challenges:||
Figure 2.Global Brain Cancer Therapeutics Market Share (%), by Distribution Channel, 2021
Increasing R&D spending for the development of new treatment methods and medical equipment is expected to drive the market growth during the forecast period.
The increasing R&D spending for the development of new treatment methods and medical equipment is expected to drive the market growth during the forecast period. For instance, according to a study published by ‘Nature Medicine’ in January 2020, a novel method that combines advanced optical imaging with an artificial intelligence algorithm was found to produce accurate and real-time intraoperative diagnosis of brain tumors in less than 3 minutes.
Global Brain Cancer Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on 30 January 2020.
COVID-19 is a viral infection and any type of infection puts brain tumor patients in more danger because of more susceptibility as the patients are already immune-suppressed. Even if they are not on steroids, all brain tumor patients are already immune-suppressed, and COVID 19 can further put them at a higher risk and make it more difficult to finish the clinical trials effectively.
Oncology is the world’s most valuable pharmaceutical sector and will continue to be the same, driven by more innovation throughout the next decade and beyond. For instance, according to an article published by McKinsey & Company, on September 2020, Oncology is a declared focus area for the ten largest pharmaceutical companies, with an estimated 1,700 clinical compounds in development which is approximately one-third of the global clinical pipeline. However, the COVID-19 pandemic crisis has clearly had considerable impact on the practice of cancer treatment, the consequences of which are expected to be felt for some time to come.
Global Brain Cancer Therapeutics Market: Restraint
The major factors that hinder the growth of the global brain cancer therapeutics market include lack of expertise and inadequate knowledge about brain cancer, few brain cancer specific drugs, high cost of treatment, and lesser accessibility.
Major players operating in the global brain cancer therapeutics market include Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Pfizer Inc., GlaxoSmithKline PLC, Novartis AG, Johnson & Johnson, Merck & Co, Bayer AG, and Bristol-Myers Squibb Company
Cancer is one of the most prevalent and fatal chronic disorders with a high mortality rate. Throughout our lives, healthy cells in our bodies divide and replace themselves in a controlled fashion. Cancer starts when a cell is altered and it multiplies out of control. A tumor is formed when such abnormal cells grow to form a mass. Cancer cells grow to form tumor that interfere with brain functions such as muscle control, memory, sensation, and other normal bodily functions. Symptoms of brain cancer vary but often include weakness, difficulty walking, dizziness, seizures, and headaches.
The brain and spinal column make up the central nervous system (CNS), where all important functions are controlled. These functions include thought, body movements, and speech. This means that when a tumor grows in the CNS, it can affect a person's thought processes or the way they move or talk. A treatment plan is individualized and planned for each brain cancer patient depending on certain factors. The treatment plan is constructed by the doctors who are specialized in brain cancer, and treatments vary widely depending on the type of cancer, brain location of the tumor, tumor size, patient age, and the general health status of the patient. A major part of the plan is also determined by the wish of the patient.
The increasing launches of new drugs and regulatory approvals for brain cancer therapeutics are expected to drive the market growth during the forecast period. For instance, in June 2020, Food and Drug Administration (FDA) has granted fast track designation to TVAX Biomedical, Inc. for TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme. TVI-Brain-1 (TVAX Biomedical) is an autologous, vaccine-enhanced adoptive T-cell therapy consisting a proprietary vaccine pretreatment to create cancer-specific T cells and an activated antitumor T-cell treatment. The Fast Track Designation was supported by positive Phase 2 clinical data in addition to extensive preclinical and Phase 1 safety studies.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.